These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 19835667)

  • 1. P-glycoprotein inhibition potentiates the behavioural and neurochemical actions of risperidone in rats.
    Pacchioni AM; Gabriele A; Donovan JL; DeVane CL; See RE
    Int J Neuropsychopharmacol; 2010 Sep; 13(8):1067-77. PubMed ID: 19835667
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dose-related effects of clozapine and risperidone on the pattern of brain regional serotonin and dopamine metabolism and on tests related to extrapyramidal functions in rats.
    Batool F; Hasnat A; Haleem MA; Haleem DJ
    Acta Pharm; 2010 Jun; 60(2):129-40. PubMed ID: 21134850
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Short- and long-term effects of risperidone on catalepsy sensitisation and acquisition of conditioned avoidance response: Adolescent vs adult rats.
    Moe AAK; Medely GA; Reeks T; Burne THJ; Eyles DW
    Pharmacol Res; 2017 Jul; 121():1-13. PubMed ID: 28414178
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Unique activation of extracellular striato-pallidal neurotransmitters in rats following acute risperidone.
    Grimm JW; See RE
    Brain Res; 1998 Aug; 801(1-2):182-9. PubMed ID: 9729373
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acute and subacute effects of risperidone and cocaine on accumbens dopamine and serotonin release using in vivo microvoltammetry on line with open-field behavior.
    Broderick PA; Rahni DN; Zhou Y
    Prog Neuropsychopharmacol Biol Psychiatry; 2003 Sep; 27(6):1037-54. PubMed ID: 14499322
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ACP-103, a 5-hydroxytryptamine 2A receptor inverse agonist, improves the antipsychotic efficacy and side-effect profile of haloperidol and risperidone in experimental models.
    Gardell LR; Vanover KE; Pounds L; Johnson RW; Barido R; Anderson GT; Veinbergs I; Dyssegaard A; Brunmark P; Tabatabaei A; Davis RE; Brann MR; Hacksell U; Bonhaus DW
    J Pharmacol Exp Ther; 2007 Aug; 322(2):862-70. PubMed ID: 17519387
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 5-HT6 receptor antagonist SB-399885 potentiates haloperidol and risperidone-induced dopamine efflux in the medial prefrontal cortex or hippocampus.
    Li Z; Huang M; Prus AJ; Dai J; Meltzer HY
    Brain Res; 2007 Feb; 1134(1):70-8. PubMed ID: 17207474
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diminished catalepsy and dopamine metabolism distinguish aripiprazole from haloperidol or risperidone.
    Nakai S; Hirose T; Uwahodo Y; Imaoka T; Okazaki H; Miwa T; Nakai M; Yamada S; Dunn B; Burris KD; Molinoff PB; Tottori K; Altar CA; Kikuchi T
    Eur J Pharmacol; 2003 Jul; 472(1-2):89-97. PubMed ID: 12860477
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination of the phosphodiesterase 10A inhibitor, MR1916 with risperidone shows additive antipsychotic-like effects without affecting cognitive enhancement and cataleptic effects in rats.
    Arakawa K; Maehara S
    Neuropsychopharmacol Rep; 2020 Jun; 40(2):190-195. PubMed ID: 32351052
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adjunctive alpha2-adrenoceptor blockade enhances the antipsychotic-like effect of risperidone and facilitates cortical dopaminergic and glutamatergic, NMDA receptor-mediated transmission.
    Marcus MM; Wiker C; Frånberg O; Konradsson-Geuken A; Langlois X; Jardemark K; Svensson TH
    Int J Neuropsychopharmacol; 2010 Aug; 13(7):891-903. PubMed ID: 19835668
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dissociation between in vivo occupancy and functional antagonism of dopamine D2 receptors: comparing aripiprazole to other antipsychotics in animal models.
    Natesan S; Reckless GE; Nobrega JN; Fletcher PJ; Kapur S
    Neuropsychopharmacology; 2006 Sep; 31(9):1854-63. PubMed ID: 16319908
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of amphetamine-induced hyperlocomotion and catalepsy following long-acting risperidone administration in rats.
    Marchese G; Casu G; Casti P; Spada GP; Pani L
    Eur J Pharmacol; 2009 Oct; 620(1-3):36-41. PubMed ID: 19664616
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of chronic risperidone treatment on the striatal protein profiles in rats.
    O'Brien E; Dedova I; Duffy L; Cordwell S; Karl T; Matsumoto I
    Brain Res; 2006 Oct; 1113(1):24-32. PubMed ID: 16938284
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of chronic co-treatment with risperidone and novel antidepressant drugs on the dopamine and serotonin levels in the rats frontal cortex.
    Kamińska K; Górska A; Noworyta-Sokołowska K; Wojtas A; Rogóż Z; Gołembiowska K
    Pharmacol Rep; 2018 Oct; 70(5):1023-1031. PubMed ID: 30144663
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alterations in brain extracellular dopamine and glycine levels following combined administration of the glycine transporter type-1 inhibitor Org-24461 and risperidone.
    Nagy K; Marko B; Zsilla G; Matyus P; Pallagi K; Szabo G; Juranyi Z; Barkoczy J; Levay G; Harsing LG
    Neurochem Res; 2010 Dec; 35(12):2096-106. PubMed ID: 20725779
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potentiation of domperidone-induced catalepsy by a P-glycoprotein inhibitor, cyclosporin A.
    Tsujikawa K; Dan Y; Nogawa K; Sato H; Yamada Y; Murakami H; Ohtani H; Sawada Y; Iga T
    Biopharm Drug Dispos; 2003 Apr; 24(3):105-14. PubMed ID: 12673668
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The PDE10A inhibitor MP-10 and haloperidol produce distinct gene expression profiles in the striatum and influence cataleptic behavior in rodents.
    Gentzel RC; Toolan D; Roberts R; Koser AJ; Kandebo M; Hershey J; Renger JJ; Uslaner J; Smith SM
    Neuropharmacology; 2015 Dec; 99():256-63. PubMed ID: 26044638
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Behavioural effects of chronic haloperidol and risperidone treatment in rats.
    Karl T; Duffy L; O'brien E; Matsumoto I; Dedova I
    Behav Brain Res; 2006 Aug; 171(2):286-94. PubMed ID: 16697060
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Further neurochemical and behavioural investigation of Brattleboro rats as a putative model of schizophrenia.
    Cilia J; Gartlon JE; Shilliam C; Dawson LA; Moore SH; Jones DN
    J Psychopharmacol; 2010 Mar; 24(3):407-19. PubMed ID: 19204063
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lack of cataleptogenic potentiation with non-imidazole H3 receptor antagonists reveals potential drug-drug interactions between imidazole-based H3 receptor antagonists and antipsychotic drugs.
    Zhang M; Ballard ME; Pan L; Roberts S; Faghih R; Cowart M; Esbenshade TA; Fox GB; Decker MW; Hancock AA; Rueter LE
    Brain Res; 2005 May; 1045(1-2):142-9. PubMed ID: 15910772
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.